Skip to main
CLDX
CLDX logo

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics Inc. has demonstrated significant progress in clinical trials, with up to 82% of patients reporting well-controlled or completely controlled chronic spontaneous urticaria, alongside a 95% improvement in quality of life metrics. The company ended the year with a robust financial position, holding $725.3 million in cash, which management anticipates will sustain operations through 2027. Furthermore, the advancement of barzolvolimab across multiple indications reinforces the company's commitment to enhancing patient health outcomes, evidenced by sustained improvements in sleep quality, social functioning, and overall mental health for affected individuals.

Bears say

The negative outlook for Celldex Therapeutics Inc. is primarily driven by the potential risks associated with failed or inconclusive clinical trials, which can significantly impact the company's progress and viability. Additionally, the company's ability to secure adequate funding is crucial to advancing its therapeutics through the development pathway, and any shortfall in this area could hinder its operational capabilities. The substantial unmet need in the treatment of various cancers, highlighted by the current two-thirds of patients not achieving complete control with existing therapies, underscores the high stakes in the company's development efforts, further amplifying the risks involved.

Celldex Therapeutics (CLDX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 17 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.